By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Alkermes Pharma Ireland Ltd. et al. v. Torrent Pharmaceuticals Ltd. et al.
1:11-cv-01009; filed October 21, 2011 in the District Court of Delaware
• Plaintiffs: Alkermes Pharma Ireland Ltd.; Jazz Pharmaceuticals Inc.
• Defendants: Torrent Pharmaceuticals Ltd.; Torrent Pharma Inc.
Infringement of U.S. Patent No. 7,456,462 ("Multiparticulate Controlled Release Selective Serotonin Reuptake Inhibitor Formulations," issued December 16, 2008), licensed to Jazz Pharmaceuticals, following a Paragraph IV certification as part of Torrent's filing of an ANDA to manufacture a generic version of Jazz's Luvox® CR (fluvoxamine maleate, used to treat social anxiety disorder and obsessive compulsive disorder). View the complaint here.
Fred Hutchinson Cancer Research Center et al. v. Branhaven, LLC
3:11-cv-00710; filed October 21, 2011 in the Eastern District of Virginia
• Plaintiffs: Fred Hutchinson Cancer Research Center; Argus Genetics, LLC; Mars, Inc.
• Defendant: Branhaven, LLC; Scidera, INC.; Scidera Canine, LLC
Infringement of U.S. Patent No. 7,729,863 ("Methods and Materials for Canine Breed Identification," issued June 1, 2010) based on defendants' use, sale, and offers to sell its dog breed identification services (Canine Heritage XL Breed Test). View the complaint here.
Janssen Pharmaceuticals, Inc. v. Sun Pharma Global FZE et al.
2:11-cv-06089; filed October 17, 2011 in the District Court of New Jersey
• Plaintiff: Janssen Pharmaceuticals, Inc.
• Defendants: Sun Pharma Global FZE; Sun Pharmaceutical Industries, Inc.
Infringement of U.S. Patent No. 6,214,815 ("Triphasic Oral Contraceptive," issued April 10, 2001) following a Paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of Ortho-McNeil's Ortho Tri-Cyclen® Lo (norgestimate and ethinyl estradiol, used for oral contraception). View the complaint here.
Novo Nordisk Inc. et al. v. Sandoz Inc.
3:11-cv-06106; filed October 14, 2011 in the District Court of New Jersey
• Plaintiffs: Novo Nordisk Inc.; Novo Nordisk A/S
• Defendant: Sandoz Inc.
Infringement of U.S. Patent No. 6,677,358 ("NIDDM Regimen," issued January 13, 2004) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Novo Nordisk's Prandin® (repaglinide, used to treat non-insulin dependent diabetes mellitus in combination with metformin). View the complaint here.
Alcon Pharmaceuticals, Ltd. vs. Perrigo Co.
4:11-cv-00732; filed October 14, 2011 in the Northern District of Texas
• Plaintiff: Alcon Pharmaceuticals, Ltd.
• Defendants: Perrigo Co; Perrigo Israel Pharmaceuticals Ltd.
Infringement of U.S. Patent No. 7,977,376 ("Olopatadine Formulations for Topical Nasal Administration," issued July 12, 2011) following a Paragraph IV certification as part of Perrigo's filing of an ANDA to manufacture a generic version of Alcon's Patanase® (olopatadine hydrochloride, used to treat seasonal allergic rhinitis). View the complaint here.
Noven Pharmaceuticals, Inc. v. Watson Laboratories, Inc. et al.
2:11-cv-05997; filed October 13, 2011 in the District Court of New Jersey
• Plaintiff: Noven Pharmaceuticals, Inc.
• Defendants: Watson Laboratories, Inc.; Watson Pharmaceuticals, Inc.
Infringement of U.S. Patent Nos. 6,210,705 ("Compositions and Methods For Treatment of Attention Deficit Disorder and Attention Deficit/Hyperactivity Disorder With Methylphenidate," issued April 3, 2001) and 6,348,211 (same title, issued February 19, 2002) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Noven's Daytrana® (transdermal methylphenidate delivery system, used to treat attention deficit disorder and attention deficit/hyperactivity disorder). View the complaint here.
Schering Corp. et al. v. Actavis Inc. et al.
2:11-cv-06067; filed October 13, 2011 in the District Court of New Jersey
• Plaintiffs: Schering Corp.; MSP Singapore Company LLC
• Defendants: Actavis Inc.; Actavis Group HF
Infringement of U.S. Patent Nos. RE42,461 ("Hydroxy-Substituted Azetidinone Compounds Useful as Hypocholesterolemic Agents," issued June 14, 2011) and 5,846,966 ("Combinations of Hydroxy-Aubstituted Azetidinone Compounds and HMG CoA Reductase Inhibitors," issued December 8, 1998), both licensed to MSP, following a Paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of MSP's Vytorin® (ezetimibe and simvastatin, used to treat hyperlipidemia). View the complaint here.
Warner Chilcott Co., LLC et al. v. Watson Pharmaceuticals, Inc. et al.
2:11-cv-05989; filed October 12, 2011 in the District Court of New Jersey
• Plaintiffs: Warner Chilcott Co., LLC; Warner Chilcott (US), LLC
• Defendants: Watson Pharmaceuticals, Inc.; Watson Laboratories, Inc. – Florida; Watson Pharma, Inc.
Infringement of U.S. Patent Nos. 7,645,459 ("Dosage Forms of Bisphosphonates," issued January 12, 2010) and 7,645,460 ("Dosage Forms of Risedronate" issued January 12, 2010) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Warner Chilcott's Atelvia (risedronate sodium delayed-release, used to treat osteoporosis in women after menopause). View the complaint here.
Comments